Chelsea Therapeutics International 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 12, 2012
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2012 annual meeting of stockholders for Chelsea Therapeutics International, Ltd. was held on June 12, 2012.
At the meeting, our stockholders elected seven members to our board of directors for a term expiring at the annual meeting of stockholders in 2013, as follows:
At the meeting, our stockholders approved the advisory resolution approving the compensation of our named executive officers as presented in the Company’s proxy statement related to the annual meeting. The vote for such proposal was 23,935,610 shares for, 13,338,586 shares against (including abstentions) and 16,753,386 broker non-votes.
The stockholders also approved an amendment to the Chelsea Therapeutics International, Ltd. 2004 Stock Plan to increase the number of shares available for issuance under the plan by 3,000,000 shares, from 7,400,000 shares to 10,400,000 shares. The vote for such proposal was 23,754,032 shares for, 13,520,164 shares against (including abstentions) and 16,753,386 broker non-votes.
At the meeting, our stockholders also ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2012. The vote for such ratification was 53,540,061 shares for and 487,521 shares against (including abstentions).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.